A genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsy

Doug Speed, Clive Hoggart, Slave Petrovski, Ioanna Tachmazidou, Alison Coffey, Andrea Jorgensen, Hariklia Eleftherohorinou, Maria De Iorio, Marian Todaro, Tisham De, David Smith, Philip E. Smith, Margaret Jackson, Paul Cooper, Mark Kellett, Stephen Howell, Mark Newton, Raju Yerra, Meng Tan, Chris FrenchMarkus Reuber, Graeme E. Sills, David Chadwick, Munir Pirmohamed, David Bentley, Ingrid Scheffer, Samuel Berkovic, David Balding, Aarno Palotie, Anthony Marson, Terence J. O'Brien, Michael R. Johnson

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


We present the analysis of a prospective multicentre study to investigate genetic effects on the prognosis of newly treated epilepsy. Patients with a new clinical diagnosis of epilepsy requiring medication were recruited and followed up prospectively. The clinical outcome was defined as freedom from seizures for a minimum of 12 months in accordance with the consensus statement from the International League Against Epilepsy (ILAE). Genetic effects on remission of seizures after starting treatment were analysed with and without adjustment for significant clinical prognostic factors, and the results from each cohort were combined using a fixedeffects meta-analysis. After quality control (QC), we analysed 889 newly treated epilepsy patients using 472 450.

Original languageEnglish
Article numberddt403
Pages (from-to)247-258
Number of pages12
JournalHuman Molecular Genetics
Issue number1
Publication statusPublished - Jan 2014
Externally publishedYes

Cite this